Presentation is loading. Please wait.

Presentation is loading. Please wait.

(A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects. (A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects.

Published byConstance Williams Modified over 4 years ago

Similar presentations

Presentation on theme: "(A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects. (A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects."— Presentation transcript:

1 (A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects.
(A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects. Insulin and amylin have similar diurnal profiles, with low basal levels and robust increases in plasma glucose after major meals. Adapted from ref. 28. (B) Mean amylin (standard error) plasma concentration versus time after a li-quid Sustacal meal. Amylin response in patients with type 1 or type 2 diabetes is demonstrated after a liquid Sustacal meal. Amylin is absent in patients with type 1 diabetes, and amylin secretion is markedly impaired in insulin-requiring patients with type 2 diabetes. Adapted from ref. 29. John B. Buse et al. Clin Diabetes 2002;20: ©2002 by American Diabetes Association

Download ppt "(A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects. (A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects."

Similar presentations

Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes A double-tracer study.

Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes A double-tracer study.
GLP-1 Effectiveness, Mechanisms of Action and Potential Part 2.

GLP-1 Effectiveness, Mechanisms of Action and Potential Part 2.
Independent variables (baseline) Loge (HOMA-IR) b P

Independent variables (baseline) Loge (HOMA-IR) b P
Glucose tolerance testing. A

Glucose tolerance testing. A
Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance.

Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance.
Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.

Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.
Athena Philis-Tsimikas, MD  The American Journal of Medicine 

Athena Philis-Tsimikas, MD  The American Journal of Medicine 
Figure 2 Evidence for the incretin effect and

Figure 2 Evidence for the incretin effect and
Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.
Insulin and glucagon secretion: nondiabetic and diabetic subjects.

Insulin and glucagon secretion: nondiabetic and diabetic subjects.
Continuous glucose monitoring tracings of two patients with type 1 diabetes (one patient per panel) on a day when aerobic exercise was performed (open.

Continuous glucose monitoring tracings of two patients with type 1 diabetes (one patient per panel) on a day when aerobic exercise was performed (open.
Glucose homeostasis: roles of insulin, glucagon, amylin, and GLP-1.

Glucose homeostasis: roles of insulin, glucagon, amylin, and GLP-1.
Depicted are patient and disease factors used to determine optimal A1C targets. Depicted are patient and disease factors used to determine optimal A1C.

Depicted are patient and disease factors used to determine optimal A1C targets. Depicted are patient and disease factors used to determine optimal A1C.
Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.
Impact of U-100 RHI administered with V-Go at OV1 (3 months after initiation) and OV2 (6 months after initiation) (n = 11) at 3 months (P = 0.32) and at.

Impact of U-100 RHI administered with V-Go at OV1 (3 months after initiation) and OV2 (6 months after initiation) (n = 11) at 3 months (P = 0.32) and at.
Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.
Patient flow chart: the final prospective study population consisted of 521 individuals, 113 on basal insulin and 408 on OADs. *Plausibility: height (130–230 cm),

Patient flow chart: the final prospective study population consisted of 521 individuals, 113 on basal insulin and 408 on OADs. *Plausibility: height (130–230 cm),
Dandan Wang et al. BTS 2018;3:350-362 Down-Regulation of miR-24 in Response to Insulin Infusion in Human Plasma Human plasma insulin (A), glucose (B),

Dandan Wang et al. BTS 2018;3: Down-Regulation of miR-24 in Response to Insulin Infusion in Human Plasma Human plasma insulin (A), glucose (B),
Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.

Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.
Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Similar presentations

Ads by Google